Loading…
Loading…
Phase 2b · Opening to enrollment soon
ClinicalTrials.gov · NCT07709845also known as the suNR1se II TrialThe Phase 2b study, entitled “A Phase 2b, Prospective, Randomized, Multi-Center, Double-Blinded, Controlled Trial To Assess the Efficacy and Safety of Stereotactic Intracerebral Transplantation of Allogeneic Neural Stem Cells CC-101 (f/k/a NR1) in Adults with Chronic Ischemic Subcortical ± Cortical Stroke,” is a randomized, controlled trial designed to evaluate the efficacy and safety of CC-101 in a larger population of chronic ischemic stroke patients with motor deficits.
Window of Eligibility
6 months to 7 years post-stroke
Population
Chronic ischemic stroke with stable motor deficits
Design
Randomized, controlled
Primary Efficacy Endpoint
Change in motor function (upper and lower extremity) between baseline and 365 days after treatment
CC-101 Dose
5.0 million cells
Status
Opening to enrollment soon
Information on this page is provided for educational purposes. Clarion Cells does not provide medical advice. Please consult your physician for treatment decisions. Clinical trial participation is subject to eligibility criteria.